Federal Register of Legislation - Australian Government

Primary content

Arrangements as made
These Arrangements provide for the supply of pharmaceutical benefits to patients of remote area Aboriginal Health Services.
Administered by: Health
Registered 31 May 2007
Date of repeal 01 Jan 2009
Repealed by National Health Act 1953 - Special Arrangement Made Under Paragraph 100(1)(a) - Remote Aboriginal Health Services Program (No. PB 57 of 2009)

COMMONWEALTH OF AUSTRALIA

 

National Health Act 1953

 

PART VII — PHARMACEUTICAL BENEFITS

 

Arrangements under paragraph 100(1)(a)

 

 

I, ALLAN RAYMOND RENNIE, Assistant Secretary, Pharmaceutical Access and Quality Branch, Department of Health and Ageing and delegate of the Minister for Health and Ageing, pursuant to paragraph 100(1)(a) of the National Health Act 1953 (“the Act”), hereby make the following arrangements for the purpose of providing that an adequate pharmaceutical service will be available to persons living in isolated areas, by providing access by patients of remote area Aboriginal Health Services to a range of essential pharmaceutical benefit items:

 

1.         These arrangements commence on 17 February 2003.

 

2.         The arrangements under paragraph 100(1)(a) of the Act for the supply of pharmaceutical benefits to patients of remote area Aboriginal Health Services made on 11 February 2000 are hereby revoked.

 

3.         The arrangements under paragraph 100(1)(a) of the Act for the supply of pharmaceutical benefits to patients of remote area Aboriginal Health Services are those set out in the Schedule to these arrangements.

 

 

Dated this 14th  day of  February 2003.

 

 

 

 

 

 

ALLAN RAYMOND RENNIE

Assistant Secretary

Pharmaceutical Access and Quality Branch

Department of Health and Ageing

Delegate of the Minister for Health and Ageing

 

 


THE SCHEDULE

 

 

Eligibility

 

The eligibility criteria for the purposes of these arrangements are:

 

1.       The Aboriginal Health Service (AHS) must have a primary function of meeting the health care needs of Aboriginal and Torres Strait Islander peoples.

 

2.       The clinic or other health care facility operated by the AHS from which pharmaceutical benefits are supplied to patients must be in a remote zone as defined in the Rural, Remote and Metropolitan Areas Classification, 1991 Census Edition.

 

3.       The AHS must not be a party to an arrangement, such as a coordinated care trial, for which funds from the Pharmaceutical Benefits Scheme have already been provided.

 

4.       The AHS must employ, or be in a contractual relationship with, health professionals who are suitably qualified under the legislation of the relevant State or Territory to supply all pharmaceutical benefits covered by these arrangements, and must undertake that all supply of pharmaceutical benefits will be made under the direction of such qualified persons.

 

5.       The clinic or other health care facility operated by the AHS from which pharmaceutical benefits are supplied must have storage facilities that will:

 

·        prevent access by unauthorised persons;

·        maintain the quality (eg chemical and biological stability and sterility) of the pharmaceutical benefit; and

·         comply with any special conditions specified by the manufacturer of the pharmaceutical benefit.

 

Scope

 

PBS medicines available through these arrangements include items contained in Section 2 of the Schedule of Pharmaceutical Benefits, in force at the time of supply, excluding:

·        pharmaceutical benefit items supplied to medical practitioners as emergency drug (Doctor’s Bag) supplies, pursuant to section 93 of the Act; and

·        pharmaceutical benefit items in respect of which special arrangements are in force under paragraph 100(1)(b) of the Act; and

·        pharmaceutical benefit items that are Schedule 8 drugs, as defined by the relevant State or Territory drugs and poisons legislation.

 

Obtaining pharmaceutical benefit items

 

Each participating remote area AHS will maintain a stock of pharmaceutical benefit items, ordered using an approval form on a bulk supply basis from an approved pharmacist or an approved hospital authority, and dispensed through the AHS as appropriate.  Pharmaceutical benefit items must be supplied directly by the approved pharmacist or the approved hospital authority to the participating AHS.  Approved pharmacists and approved hospital authorities will be reimbursed directly by the Health Insurance Commission (HIC).

 

Dispensing

 

Pharmaceutical benefit items will be dispensed to patients by an appropriate health professional (either a medical practitioner, or an Aboriginal Health Worker or nurse working under the supervision of a medical practitioner, where consistent with the law of the relevant State or Territory).  A patient who is supplied with a pharmaceutical benefit under these arrangements is not to be charged a patient copayment.

 

Claims system

 

Each AHS will be registered with the HIC and, if there are several remote area clinics operating under the auspices of a large AHS or a State or Territory Government Agency, a unique approval number will be allocated to each clinic.  The approved pharmacist or approved hospital authority will maintain a record of pharmaceutical benefit items supplied to each approved AHS, and will provide this information to the HIC as the basis for reimbursement.

 

Remuneration

 

Reimbursement by the Commonwealth of approved pharmacists and approved hospital authorities for supplying pharmaceutical benefit items to AHSs under these arrangements will be the sum of the following:

 

·                   the approved price to pharmacists within the meaning of subsection 98B(3) of the Act; and

 

·                   mark-up at the rate specified in the determination under paragraph 98B(1)(a) of the Act that is in force at the time of supply of the benefit; and

 

·                   a handling fee, calculated as the difference between the dispensing fee for the supply of a ready-prepared pharmaceutical benefit, specified in the determination under paragraph 98B(1)(a) of the Act that is in force at the time of supply of the benefit, and the concessional patient copayment applicable under paragraph 87(2)(a) of the Act at the time of supply of the benefit, or $1.14, whichever is greater.

 

Costs of transportation and cold chain maintenance are included in the above reimbursement formula.